Table 1.
Patient characteristics.
| All patients (n = 209) |
Lung cancer patients (n = 112) |
|
|---|---|---|
| Age | ||
| Median (range: 25th-75th percentiles) | 68 (57-74) | 68 (60-75) |
| Sex | ||
| Male | 144 | 77 |
| Female | 65 | 35 |
| ECOG PS | ||
| 0 | 65 | 25 |
| 1 | 118 | 71 |
| 2 | 23 | 16 |
| 3 | 3 | 0 |
| Primary tumor | ||
| Lung cancer | 112 | 112 |
| Renal cell carcinoma | 33 | — |
| Malignant melanoma | 35 | — |
| Gastric cancer | 29 | — |
| Smoking history | ||
| Yes | 125 | 80 |
| Never | 65 | 30 |
| Unknown | 19 | 2 |
| Prior radiation | ||
| Thoracic | 35 | 33 |
| Extra-thoracic | 33 | 19 |
| None | 141 | 60 |
| Types of ICIs | ||
| Nivolumab | 170 | 77 |
| Pembrolizumab | 33 | 29 |
| Atezolizumab | 6 | 6 |
| ICI treatment line | ||
| 1 | 37 | 17 |
| 2 | 72 | 48 |
| ≥3 | 100 | 47 |
| Duration of ICI administration | ||
| Median months (range: 25th-75th percentiles) | 3.79 (1.50-10.82) | 3.38 (1.40-10.12) |
| Reason for discontinuation of ICIs | ||
| IrAEs | 40 | 25 |
| Progression of disease | 121 | 66 |
| Ongoing ICIs | 35 | 15 |
| Others | 13 | 6 |
| Number of IrAE | ||
| 0 | 102 | 49 |
| 1 | 65 | 38 |
| ≥2 | 42 | 25 |
| Laboratory findings | ||
| Neutrophil-to-lymphocyte ratio | ||
| Median (range: 25th-75th percentiles) | 3.33 (2.01-5.33) | 3.64 (2.32-6.59) |
| KL-6 (U/mL) | ||
| Median (range: 25th-75th percentiles) | 359 (239-593) | 475 (307-778) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; IrAE, immune related adverse event; KL-6, Krebs von den lungen-6; PS, performance status.